1. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications;Howden;Clin Microbiol Rev.,2010
2. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines;Lynch;Curr Opin Pulm Med.,2010
3. Ceftaroline: a new broad-spectrum cephalosporin;Lim;Am J Health-Syst Pharm.,2011
4. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections;Corey;J Antimicrob Chemother.,2010
5. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections;Wilcox;J Antimicrob Chemother.,2010